Australian Clinical Labs Limited

ASX:ACL Voorraadrapport

Marktkapitalisatie: AU$715.8m

Australian Clinical Labs Beheer

Beheer criteriumcontroles 3/4

De CEO Australian Clinical Labs is Melinda McGrath, benoemd in Dec2020, heeft een ambtstermijn van 3.92 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.56M, bestaande uit 55.9% salaris en 44.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.09% van de aandelen van het bedrijf, ter waarde A$ 7.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.4 jaar en 3.6 jaar.

Belangrijke informatie

Melinda McGrath

Algemeen directeur

AU$1.6m

Totale compensatie

Percentage CEO-salaris55.9%
Dienstverband CEO3.9yrs
Eigendom CEO1.1%
Management gemiddelde ambtstermijn5.4yrs
Gemiddelde ambtstermijn bestuur3.6yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Jun 20
We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Feb 21
Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Dec 08
Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14
Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25
Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22
New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21
The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01
The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Analyse CEO-vergoeding

Hoe is Melinda McGrath's beloning veranderd ten opzichte van Australian Clinical Labs's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024AU$2mAU$873k

AU$24m

Mar 31 2024n/an/a

AU$20m

Dec 31 2023n/an/a

AU$15m

Sep 30 2023n/an/a

AU$26m

Jun 30 2023AU$1mAU$873k

AU$36m

Mar 31 2023n/an/a

AU$55m

Dec 31 2022n/an/a

AU$73m

Sep 30 2022n/an/a

AU$126m

Jun 30 2022AU$2mAU$873k

AU$178m

Mar 31 2022n/an/a

AU$156m

Dec 31 2021n/an/a

AU$134m

Sep 30 2021n/an/a

AU$97m

Jun 30 2021AU$2mAU$875k

AU$60m

Mar 31 2021n/an/a

AU$79m

Dec 31 2020n/an/a

AU$98m

Sep 30 2020n/an/a

AU$70m

Jun 30 2020AU$2mAU$852k

AU$41m

Compensatie versus markt: De totale vergoeding ($USD 1.03M ) Melinda } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 923.16K ).

Compensatie versus inkomsten: De beloning van Melinda is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Melinda McGrath

3.9yrs

Tenure

AU$1,560,335

Compensatie

Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020. She served as Chief Executive Officer and Executive Director at Clinical L...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Melinda McGrath
CEO & Executive Director3.9yrsAU$1.56m1.09%
A$ 7.8m
Darren McKee
Chief Executive Officer of Victoria1.8yrsAU$37.27kgeen gegevens
Matthew Cordingley
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Anthony Friedli
Chief Operating Officer8.8yrsgeen gegevens0%
A$ 0
Sean Jackson
Chief Information Officer9.8yrsgeen gegevensgeen gegevens
Joe Geran
National Marketing Directorno datageen gegevensgeen gegevens
Tony Landgren
National Medical Director & Chief Pathologist15.8yrsgeen gegevens0%
A$ 0
Chris Brownlow
Chief Executive Officer of New South Wales & Australian Capital Territory13.8yrsgeen gegevensgeen gegevens
Shae Seymour
Chief Executive Officer of WA/SA/NT6.8yrsgeen gegevensgeen gegevens
Eleanor Padman
Company Secretary3.6yrsgeen gegevensgeen gegevens
Rob Izzard
Chief Executive Officer of ACL Commercial Pathology1.8yrsgeen gegevensgeen gegevens

5.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van ACL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Melinda McGrath
CEO & Executive Director3.9yrsAU$1.56m1.09%
A$ 7.8m
Michael Alscher
Non-Executive Chairman1.2yrsAU$152.73k0.14%
A$ 1.0m
Christine Bartlett
Independent Non-Executive Director1.3yrsAU$111.74k0.010%
A$ 71.6k
Leanne Rowe
Independent Non-Executive Director3.6yrsAU$131.18k0.0025%
A$ 17.9k
Mark Haberlin
Independent Non-Executive Director3.6yrsAU$136.23k0.024%
A$ 170.1k

3.6yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).